Current and historical daily PE Ratio for GBIM (
GlobeImmune Inc
) from 2014 to May 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. GlobeImmune stock (GBIM) PE ratio as of May 21 2024 is 0.
More Details
GlobeImmune Inc (GBIM) PE Ratio (TTM) Chart
GlobeImmune Inc (GBIM) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 0
- 1
| GlobeImmune PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
GlobeImmune Inc (GBIM) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
GlobeImmune Inc
NAICS : 325412
SIC : 2834
ISIN : US37957B1008
Compare
Compare
Traded in other countries / regions
GBIM.USA IPO Date
2014-07-02Description
GlobeImmune Inc is a U.S.-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers